Skip to content
Simpler Grants

No. RFA-CA-27-001 · National Institutes of Health

Open

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

grants.gov listing
Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Award range
Up to $150,000
Expected awards
~20
Application deadline
Nov 10, 2026
Posted
Jun 3, 2026
Last verified
2 days ago

At a glance

No plain-language summary yet for this grant — the official description below is the best source.

What it funds

  • Health
  • Technology & Product Development
  • Researchers & Scholars
  • Biomedical & Disease Research
Official description from grants.gov

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Who can apply

  • City or township governments
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities / Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Geographic restriction None found in the announcement — likely nationwide

Program history

USASpending.gov

Assistance listing 93.394 · Cancer Detection and Diagnosis Research

Real awards this federal program has made — the whole assistance listing (93.394), not just this notice.

Fiscal year Awards Median award Middle half
FY 2026 (so far) 137 $595,012 $414,585 – $662,610
FY 2025 184 $726,875 $399,923 – $1,297,708
FY 2024 215 $1,129,641 $414,953 – $1,862,878
FY 2023 268 $1,754,736 $438,924 – $2,398,100
FY 2022 277 $2,036,627 $596,368 – $3,077,027
FY 2021 269 — —

For comparison, this notice advertises Up to $150,000.

Dollar figures are based on the 1,000 most recent awards we store, not all 1,350 — award counts are complete.

Who wins it Higher education (836), Nonprofit (284), Business (196) of 1,350 awards — categories can overlap.
Top states CA (184) · NY (79) · MA (78) · TX (66) · PA (26)
Largest recent awards
  1. TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE $8,347,015 · FY 2022
  2. BATTELLE MEMORIAL INSTITUTE $6,630,183 · FY 2022
  3. THE JOHNS HOPKINS UNIVERSITY $6,618,085 · FY 2022
  4. SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH $6,181,895 · FY 2022
  5. OREGON HEALTH & SCIENCE UNIVERSITY $5,771,926 · FY 2022

Source: USASpending.gov · refreshed Aug 14, 2026